Evaluation of the INDICAID COVID-19 Rapid Antigen Test in Symptomatic Populations
Laboratory-based RT-PCR, the current gold standard for COVID-19 testing, can require a turnaround time of 24 to 48 h from sample collection to result. The delayed time to result limits the effectiveness of centralized RT-PCR testing to reduce transmission and stem potential outbreaks. To address this, we conducted a thorough evaluation of the INDICAID COVID-19 rapid antigen test, a 20-minute rapid antigen test, in both symptomatic and asymptomatic populations.
The INDICAID rapid test demonstrated high sensitivity and specificity with RT-PCR as the comparator method. A dual-track testing algorithm was also evaluated utilizing the INDICAID rapid test to screen for preliminary positive patients, whose samples were then prioritized for RT-PCR testing. The dual-track method demonstrated significant improvements in expediting the reporting of positive RT-PCR test results compared to standard RT-PCR testing without prioritization, Rapid antigen test procedure offering an improved strategy for community testing and controlling SARS-CoV-2 outbreaks.
The global SARS-CoV-2 pandemic has continued despite implementation of significant public health measures .
- Over 155 million worldwide cases of COVID-19 and over 3 million COVID-19 deaths have been reported as of May 2021. Rapid identification of SARS-CoV-2 infection, patient isolation, and contact tracing are essential for disease containment (2).
- The current gold standard for detecting SARS-CoV-2 is reverse transcriptase PCR (RT-PCR) (3). While RT-PCR can detect nucleic acids from SARS-CoV-2 with high sensitivity, RT-PCR requires equipment and special training and can take days for results to be available following sample collection (4).
- Due to the transmissibility of SARS-CoV-2 (basic reproductive number R0 of 2.87), long turnaround times for results may lead to a high number of avoidable transmissions (5, 6).
- In contrast, lateral flow immunoassays (LFAs) are an inexpensive testing solution that can be used at point-of-care settings, do not require laboratory equipment, and can generate results quickly.
- However, the performance of LFA-based SARS-CoV-2 rapid antigen tests in community testing settings can vary significantly .
- In this study, we evaluated the clinical performance of the LFA-based INDICAID COVID-19 rapid antigen test (INDICAID rapid test) by PHASE Scientific International Ltd. A prospective multisite clinical study was performed in symptomatic patient populations in point-of-care (POC) community testing sites in the United States.
- The performance of the INDICAID rapid test was also evaluated in COVID-19 outbreak screening centers in Hong Kong as a part of an algorithm testing approach (termed “dual-track”) to screen for COVID-19-positive patients prior to RT-PCR testing in asymptomatic patient populations.
Prospective multisite clinical evaluation of the INDICAID COVID-19 rapid antigen test.
In total, 83 participants with at least two COVID-19 symptoms were enrolled at the San Francisco, CA and Oakland, CA sites. Two participants were excluded from the analysis due to lost samples during transport for RT-PCR. Of the 81 participant specimens analyzed, 44.4% were from female participants (Table S1), with a median age of 32 years (interquartile range [IQR], 25, 44). The most frequently reported symptoms were muscle/body ache (61.7%), congestion/runny nose (60.5%), fatigue (56.8%), and headache (53.1%). The breakdown of duration of symptoms was 1 to 2 days in 37 participants (45.7%), 3 to 4 days in 38 participants (46.9%), and 5 days in 6 participants (7.4%).
San Fernando population characteristics.
In total, 270 participants with at least one COVID-19 symptom were enrolled at the San Fernando, CA site. Two participants were excluded from the analysis due to lost or spilled samples during transport for RT-PCR. Of the 268 participant specimens analyzed, 52.6% were from female participants (Table S2), and the median age was 35 years (IQR, 24, 50). The most frequently reported symptoms were sore throat (60.8%), headache (60.1%), congestion/runny nose (59.0%), and cough (54.9%). The distribution of duration of symptoms was 1 to 2 days in 109 participants (40.7%), 3 to 4 days in 127 participants (47.4%), and 5 days in 32 participants (11.9%).
Performance of the INDICAID COVID-19 rapid antigen test in symptomatic patients.
Of the total 329 participant specimens included in the analyses, 75 tested positive with the comparator laboratory-based RT-PCR test. The mean cycle threshold value was 20.79 ± 6.39.
The INDICAID rapid test demonstrated a PPA of 85.3% (95% confidence interval [95% CI], 75.6% to 91.6%) and an NPA of 94.9% (95% CI, 91.6% to 96.9%) when sample collection was conducted by a health care professional. There was a total of 11 false-negative INDICAID results that were not concordant with RT-PCR results; the mean threshold cycle (CT) value of the false-negative INDICAID specimens was 32.56 ± 4.59.
As the COVID-19 pandemic progresses, there is an increasing need for rapid, accessible assays for SARS-CoV-2 detection. We present a clinical evaluation and real-world implementation of the INDICAID COVID-19 rapid antigen test (INDICAID rapid test). A multisite clinical evaluation of the INDICAID rapid test using prospectively collected nasal (bilateral anterior) swab samples from symptomatic subjects was performed. The INDICAID rapid test demonstrated a positive percent agreement (PPA) and negative percent agreement (NPA) of 85.3% (95% confidence interval [95% CI], 75.6% to 91.6%) and 94.9% (95% CI, 91.6% to 96.9%), respectively, compared to laboratory-based reverse transcriptase PCR (RT-PCR) using nasal specimens.
The INDICAID rapid test was then implemented at COVID-19 outbreak screening centers in Hong Kong as part of a testing algorithm (termed “dual-track”) to screen asymptomatic individuals for prioritization for confirmatory RT-PCR testing. In one approach, preliminary positive INDICAID rapid test results triggered expedited processing for laboratory-based RT-PCR, reducing the average time to confirmatory result from 10.85 h to 7.0 h.
Free Chlorine Reagent set (25 tests) |
|||
HI-701-25 | Scientific Laboratory Supplies | PK25 | 7.58 EUR |
Total Chlorine Reagent set (25 tests) |
|||
HI-711-25 | Scientific Laboratory Supplies | PK25 | 11.67 EUR |
TruStrip RDT Human Procalcitonin (PCT) Rapid Test cards, 25 tests/pack |
|||
PCT-RDT-25 | Alpha Diagnostics | 1 pack | 351.6 EUR |
Human Rena-strip Kit, 25 tests |
|||
H-RENA-LF-025 | BioAssayWorks | 25 tests | 617.3 EUR |
Rat Rena-strip Kit, 25 tests |
|||
R-RENA-LF-025 | BioAssayWorks | 25 tests | 617.3 EUR |
TruStrip RDT Human Serum Amyloid A (SAA) Rapid Test cards, 25 tests/pack |
|||
SAA-RDT-25 | Alpha Diagnostics | 1 pack | 351.6 EUR |
TruStrip RDT 5-minute Horse meat detection/adulteration rapid test cards, 25 tests/pk |
|||
RDT-6050H-25 | Alpha Diagnostics | 1 pk | 351.6 EUR |
Slide Box Blue 25 Slides |
|||
MIC3562 | Scientific Laboratory Supplies | EACH | 19.13 EUR |
Slide Box Green 25 Slides |
|||
MIC3564 | Scientific Laboratory Supplies | EACH | 19.13 EUR |
Slide Box Red 25 Slides |
|||
MIC3566 | Scientific Laboratory Supplies | EACH | 19.13 EUR |
Slide Box White 25 Slides |
|||
MIC3570 | Scientific Laboratory Supplies | EACH | 19.13 EUR |
Slide Box 25 Slide Polystyrene |
|||
MIC4066 | Scientific Laboratory Supplies | EACH | 12.54 EUR |
MTBK_20640-25 |
|||
AR02-P0011-25 | Abfrontier | 25ug | 567.6 EUR |
Economy Slide box 25 Place BLUE |
|||
MIC3580 | Scientific Laboratory Supplies | EACH | 13.32 EUR |
Economy Slide box 25 Place RED |
|||
MIC3582 | Scientific Laboratory Supplies | EACH | 13.32 EUR |
Economy Slide box 25 Place WHITE |
|||
MIC3584 | Scientific Laboratory Supplies | EACH | 14.02 EUR |
Slide Box White for 25 Slides |
|||
MIC4000 | Scientific Laboratory Supplies | EACH | 9.69 EUR |
Microscope Slide Box 25 ULT safe |
|||
MIC4092 | Scientific Laboratory Supplies | EACH | 17.62 EUR |
PC Freezer Box 25-Place 76x76x27mm |
|||
ARG1728 | Scientific Laboratory Supplies | PK4 | 71.82 EUR |
Storage Box 25 Tubes 2 inch |
|||
E0030140583 | Scientific Laboratory Supplies | PK2 | 20.75 EUR |
Storage Box 25 Tubes 3 inch |
|||
E0030140613 | Scientific Laboratory Supplies | PK2 | 20.24 EUR |
Rv0351 (GrpE)-25 |
|||
AR02-P0003-25 | Abfrontier | 25ug | 151.2 EUR |
Rv1009 (RpfB)-25 |
|||
AR02-P0006-25 | Abfrontier | 25ug | 567.6 EUR |
Rv2450c (RpfE)-25 |
|||
AR02-P0007-25 | Abfrontier | 25ug | 567.6 EUR |
Rv3875 (esxA)-25 |
|||
AR02-P0008-25 | Abfrontier | 25ug | 567.6 EUR |
Rv2031c(HspX)-25 |
|||
AR02-P0009-25 | Abfrontier | 25ug | 567.6 EUR |
Rv3131 (NfnB)-25 |
|||
AR02-P0010-25 | Abfrontier | 25ug | 567.6 EUR |
Cardboard freezer box, hinged lid, insert for 25 snap-cap 5ml tubes, 5.25 x 5.25 x 3 inches |
|||
C2580-25 | MTC Bio | 5/pack | 76.04 EUR |
26795 25 CLOSURE NTRL 25MM |
|||
26795-25 | CORNING | 50/pk | 115.2 EUR |
Mouse IL-25 ELISA Kit, 96 tests, Quantitative |
|||
MIL-025-170 | Alpha Diagnostics | 1 kit | 607.2 EUR |
Nori® Human Myoglobin POCT Systems-25 Tests |
|||
GR220006 | Genorise Scientific | 25 Tests | 358.8 EUR |
Nori® Human Myeloperoxidase POCT Systems-25 Tests |
|||
GR220007 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Human CRP POCT Systems-25 Tests |
|||
GR220008 | Genorise Scientific | 25 Tests | 358.8 EUR |
Nori® Human GPBB POCT Systems-25 Tests |
|||
GR220009 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Human ANP POCT Systems-25 Tests |
|||
GR220010 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Human MyBPC3 POCT Systems-25 Tests |
|||
GR220012 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Human PAPPA POCT Systems-25 Tests |
|||
GR220014 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Human Copeptin POCT Systems-25 Tests |
|||
GR220015 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Human ST2 POCT Systems-25 Tests |
|||
GR220016 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Human MMP2 POCT Systems-25 Tests |
|||
GR220017 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Human sPLA2 POCT Systems-25 Tests |
|||
GR220018 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Canine Myoglobin POCT Systems-25 Tests |
|||
GR221006 | Genorise Scientific | 25 Tests | 358.8 EUR |
Nori® Canine Myeloperoxidase POCT Systems-25 Tests |
|||
GR221007 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Canine CRP POCT Systems-25 Tests |
|||
GR221008 | Genorise Scientific | 25 Tests | 358.8 EUR |
Nori® Canine GPBB POCT Systems-25 Tests |
|||
GR221009 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Canine ANP POCT Systems-25 Tests |
|||
GR221010 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Canine MyBPC3 POCT Systems-25 Tests |
|||
GR221012 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Canine PAPPA POCT Systems-25 Tests |
|||
GR221014 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Canine Copeptin POCT Systems-25 Tests |
|||
GR221015 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Canine ST2 POCT Systems-25 Tests |
|||
GR221016 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Canine MMP2 POCT Systems-25 Tests |
|||
GR221017 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Canine sPLA2 POCT Systems-25 Tests |
|||
GR221018 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Feline Myoglobin POCT Systems-25 Tests |
|||
GR222006 | Genorise Scientific | 25 Tests | 358.8 EUR |
Nori® Feline Myeloperoxidase POCT Systems-25 Tests |
|||
GR222007 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Feline CRP POCT Systems-25 Tests |
|||
GR222008 | Genorise Scientific | 25 Tests | 358.8 EUR |
Nori® Feline GPBB POCT Systems-25 Tests |
|||
GR222009 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Feline ANP POCT Systems-25 Tests |
|||
GR222010 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Feline MyBPC3 POCT Systems-25 Tests |
|||
GR222012 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Feline PAPPA POCT Systems-25 Tests |
|||
GR222014 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Feline Copeptin POCT Systems-25 Tests |
|||
GR222015 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Feline ST2 POCT Systems-25 Tests |
|||
GR222016 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Feline MMP2 POCT Systems-25 Tests |
|||
GR222017 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Feline sPLA2 POCT Systems-25 Tests |
|||
GR222018 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Equine Myoglobin POCT Systems-25 Tests |
|||
GR223006 | Genorise Scientific | 25 Tests | 358.8 EUR |
Nori® Equine Myeloperoxidase POCT Systems-25 Tests |
|||
GR223007 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Equine CRP POCT Systems-25 Tests |
|||
GR223008 | Genorise Scientific | 25 Tests | 358.8 EUR |
Nori® Equine GPBB POCT Systems-25 Tests |
|||
GR223009 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Equine ANP POCT Systems-25 Tests |
|||
GR223010 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Equine MyBPC3 POCT Systems-25 Tests |
|||
GR223012 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Equine PAPPA POCT Systems-25 Tests |
|||
GR223014 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Equine Copeptin POCT Systems-25 Tests |
|||
GR223015 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Equine ST2 POCT Systems-25 Tests |
|||
GR223016 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Equine MMP2 POCT Systems-25 Tests |
|||
GR223017 | Genorise Scientific | 25 Tests | 741.6 EUR |
Nori® Equine sPLA2 POCT Systems-25 Tests |
|||
GR223018 | Genorise Scientific | 25 Tests | 741.6 EUR |
AXYGEN® 25-WELL COMB FOR USE WITH 10 CM GEL BOX, 1.0 MM THICKNESS |
|||
HGB10-25-1 | CORNING | 1/pk | 70.8 EUR |
AXYGEN® 25-WELL COMB FOR USE WITH 10 CM GEL BOX, 2.0 MM THICKNESS |
|||
HGB10-25-2 | CORNING | 1/pk | 70.8 EUR |
AXYGEN® 25-WELL COMB FOR USE WITH 20 CM GEL BOX, 1.0 MM THICKNESS |
|||
HGB20-25-1 | CORNING | 1/pk | 82.8 EUR |
TruStrip RDT Anthrax Protective antigen 83 (PA83) Rapid Test cards, 25/pk |
|||
800-100-RDT-25 | Alpha Diagnostics | 1 pk | 489.6 EUR |
Amyloid Beta-peptide (25-35) (human) |
|||
A1039-25 | ApexBio | 25 mg | 606 EUR |
Express Plasmid Midiprep Kit (25 min) |
|||
K1323-25 | Biovision | each | 561.6 EUR |
Express Plasmid Maxiprep Kit (25 min) |
|||
K1324-25 | Biovision | each | 732 EUR |
2.5x14 cellogel 250µ (25) |
|||
EHCA1200-ST06-25 | Consort | ea | 45.6 EUR |
2.5x14 cellogel 200µ (25) |
|||
EHCA1200-ST07-25 | Consort | ea | 45.6 EUR |
2.5x17 cellogel 250µ (25) |
|||
EHCA1200-ST11-25 | Consort | ea | 49.2 EUR |
2.5x17 cellogel 200µ (25) |
|||
EHCA1200-ST12-25 | Consort | ea | 49.2 EUR |
5.7x13 cellogel 250µ (25) |
|||
EHCA1200-ST29U-25 | Consort | ea | 72 EUR |
5.7x14 cellogel 250µ (25) |
|||
EHCA1200-ST31-25 | Consort | ea | 63.6 EUR |
5.7x14 cellogel 200µ (25) |
|||
EHCA1200-ST32-25 | Consort | ea | 63.6 EUR |
5.7x14 cellogel 500µ (25) |
|||
EHCA1200-ST34-25 | Consort | ea | 72 EUR |
Rv2769c (PE27 protein)-25 |
|||
AR02-P0001-25 | Abfrontier | 25ug | 243.6 EUR |
25-place microscope slide box (for 75 x 25 mm slides) |
|||
PO202 | FD Neurotechnologies | each | 73.2 EUR |
F-Box Only Protein 25 (FBXO25) Antibody |
|||
20-abx318182 | Abbexa |
|
|
Storage box 5mL tube 25 pl blue |
|||
RAC2006 | Scientific Laboratory Supplies | PK18 | 180.12 EUR |
Storage box 5mL tube 25 pl green |
|||
RAC2008 | Scientific Laboratory Supplies | PK18 | 180.12 EUR |
Storage box 5mL tube 25 pl pink |
|||
RAC2010 | Scientific Laboratory Supplies | PK18 | 180.12 EUR |
Storage box 5mL tube 25 pl yello |
|||
RAC2012 | Scientific Laboratory Supplies | PK18 | 180.12 EUR |
PREMIUM SLIDE BOX 25 PLACE FOAM LININ |
|||
HS15989R | Scientific Laboratory Supplies | EACH | 16.99 EUR |
Eye Wash Pods 20ml Box of 25 |
|||
SAF1380 | Scientific Laboratory Supplies | PK25 | 9.87 EUR |
Box for 25 microscope slides purple colour |
|||
DD49719 | Scientific Laboratory Supplies | EACH | 15.28 EUR |
Box for 25 microscope slides orange colour |
|||
DD49720 | Scientific Laboratory Supplies | EACH | 15.28 EUR |
In a second approach, preliminary positive results triggered subsequent testing with an onsite rapid RT-PCR, reducing the average time to confirmatory result to 0.84 h. In 22,994 asymptomatic patients, the INDICAID rapid test demonstrated a PPA of 84.2% (95% CI, 69.6% to 92.6%) and an NPA of 99.9% (95% CI, 99.9% to 100%) compared to laboratory-based RT-PCR using combined nasal/oropharyngeal specimens. The INDICAID rapid test has excellent performance compared to laboratory-based RT-PCR testing and, when used in tandem with RT-PCR, reduces the time to confirmatory positive result.